Clinical Trials Logo

Clinical Trial Summary

Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response. In laboratory animals the imILT method has also been shown to induce a so called abscopal effect. This means that when one tumor is treated with imILT other, untreated, tumors also decrease in size. The purpose of this trial is to evaluate efficiency when it comes to local tumor destruction of the imILT treatment method in patients diagnosed with pancreatic cancer. The purpose is also to investigate the functionality and safety as well as understanding of the subsequent immunological effects. This trial is prospective, open and non-randomized. Five patients diagnosed with pancreatic cancer will be treated in this trial, which is estimated to be carried out during a time period of 36 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02973217
Study type Interventional
Source Clinical Laserthermia Systems AB
Contact
Status Completed
Phase N/A
Start date October 2016
Completion date July 22, 2019

See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Completed NCT05547074 - A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Recruiting NCT04161417 - Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Terminated NCT04176952 - PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2